Skye Bioscience, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
This Schedule 13D filing details amendments to beneficial ownership by 5AM Ventures entities and individuals, reflecting recent share transactions and a 1-for-8 reverse stock split.
NASDAQ
Skye Bioscience announces a definitive agreement to acquire Redx Pharma Limited, alongside a $72.9 million concurrent financing and the introduction of contingent value rights.
NASDAQ
5AM Partners II, a significant shareholder in Skye Bioscience, Inc., has adopted a new 10b5-1 plan to sell up to 1.51 million shares of common stock between January and November 2026.